Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its target price hoisted by research analysts at Canaccord Genuity Group from $154.00 to $164.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 17.29% from […]
Russell Investments Group Ltd. Decreases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
New York State Common Retirement Fund lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 12.1% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 214,396 shares of the company’s stock after selling 29,456 shares during the period. New York State Common […]